Scilex (SCLX) Competitors $16.31 +1.72 (+11.79%) Closing price 04:00 PM EasternExtended Trading$16.51 +0.20 (+1.23%) As of 04:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock SCLX vs. AURA, REPL, LBRX, LRMR, ANNX, DMAC, EDIT, ALT, CTNM, and DSGNShould you be buying Scilex stock or one of its competitors? The main competitors of Scilex include Aura Biosciences (AURA), Replimune Group (REPL), LB Pharmaceuticals (LBRX), Larimar Therapeutics (LRMR), Annexon (ANNX), DiaMedica Therapeutics (DMAC), Editas Medicine (EDIT), Altimmune (ALT), Contineum Therapeutics (CTNM), and Design Therapeutics (DSGN). These companies are all part of the "pharmaceutical products" industry. Scilex vs. Its Competitors Aura Biosciences Replimune Group LB Pharmaceuticals Larimar Therapeutics Annexon DiaMedica Therapeutics Editas Medicine Altimmune Contineum Therapeutics Design Therapeutics Aura Biosciences (NASDAQ:AURA) and Scilex (NASDAQ:SCLX) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their institutional ownership, analyst recommendations, risk, earnings, media sentiment, dividends, valuation and profitability. Is AURA or SCLX more profitable? Aura Biosciences has a net margin of 0.00% compared to Scilex's net margin of -179.12%. Scilex's return on equity of 0.00% beat Aura Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets Aura BiosciencesN/A -64.44% -54.24% Scilex -179.12%N/A -109.95% Which has more risk and volatility, AURA or SCLX? Aura Biosciences has a beta of 0.45, indicating that its stock price is 55% less volatile than the S&P 500. Comparatively, Scilex has a beta of 1.36, indicating that its stock price is 36% more volatile than the S&P 500. Do insiders & institutionals believe in AURA or SCLX? 96.8% of Aura Biosciences shares are held by institutional investors. Comparatively, 69.7% of Scilex shares are held by institutional investors. 6.3% of Aura Biosciences shares are held by insiders. Comparatively, 7.9% of Scilex shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock will outperform the market over the long term. Does the media favor AURA or SCLX? In the previous week, Aura Biosciences had 1 more articles in the media than Scilex. MarketBeat recorded 1 mentions for Aura Biosciences and 0 mentions for Scilex. Aura Biosciences' average media sentiment score of 0.55 beat Scilex's score of 0.00 indicating that Aura Biosciences is being referred to more favorably in the media. Company Overall Sentiment Aura Biosciences Positive Scilex Neutral Which has preferable valuation and earnings, AURA or SCLX? Scilex has higher revenue and earnings than Aura Biosciences. Aura Biosciences is trading at a lower price-to-earnings ratio than Scilex, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAura BiosciencesN/AN/A-$86.92M-$1.96-2.99Scilex$44.24M2.56-$72.81M-$29.02-0.56 Do analysts rate AURA or SCLX? Aura Biosciences presently has a consensus target price of $20.50, suggesting a potential upside of 249.83%. Scilex has a consensus target price of $630.00, suggesting a potential upside of 3,762.66%. Given Scilex's higher possible upside, analysts plainly believe Scilex is more favorable than Aura Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Aura Biosciences 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 1 Strong Buy rating(s) 2.67Scilex 1 Sell rating(s) 2 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.67 SummaryAura Biosciences beats Scilex on 9 of the 16 factors compared between the two stocks. Get Scilex News Delivered to You Automatically Sign up to receive the latest news and ratings for SCLX and its competitors with MarketBeat's FREE daily newsletter. Subscribe Now View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding SCLX and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart SCLX vs. The Competition Export to ExcelMetricScilexMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$113.45M$3.42B$6.15B$10.77BDividend YieldN/A2.26%5.71%4.83%P/E Ratio-0.5623.3129.7228.55Price / Sales2.56271.94499.21189.70Price / CashN/A45.1236.6160.67Price / Book-0.5910.4012.016.61Net Income-$72.81M-$52.62M$3.32B$276.82M7 Day Performance27.62%2.14%1.54%1.96%1 Month Performance-42.95%10.90%6.10%2.53%1 Year Performance-47.81%13.64%61.10%32.80% Scilex Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)SCLXScilex1.9049 of 5 stars$16.31+11.8%$630.00+3,762.7%-54.4%$113.45M$44.24M-0.5680Gap UpAURAAura Biosciences1.7017 of 5 stars$6.06+6.9%$20.50+238.3%-50.2%$352.22MN/A-3.0950REPLReplimune Group4.449 of 5 stars$8.94+98.7%$11.00+23.0%-29.9%$351.25MN/A-2.76210Analyst RevisionHigh Trading VolumeLBRXLB PharmaceuticalsN/A$16.00+2.6%$30.50+90.6%N/A$350.11MN/A0.0016Quiet Period ExpirationLRMRLarimar Therapeutics3.1992 of 5 stars$4.35+3.6%$16.71+284.2%-46.3%$347.67MN/A-2.7930Upcoming EarningsANNXAnnexon1.5253 of 5 stars$3.16+0.3%$12.50+295.6%-58.4%$346.14MN/A-2.4560Analyst ForecastDMACDiaMedica Therapeutics1.0606 of 5 stars$6.77+2.9%$12.33+82.2%+54.3%$340.11MN/A-9.8120Analyst ForecastEDITEditas Medicine4.3604 of 5 stars$4.14+9.8%$5.10+23.2%+13.7%$339M$32.31M-1.45230Positive NewsAnalyst ForecastGap UpALTAltimmune2.214 of 5 stars$4.00+4.4%$17.40+335.0%-41.1%$338.02M$20K-3.3950Analyst ForecastCTNMContineum Therapeutics2.4453 of 5 stars$11.09-5.2%$22.20+100.2%-31.6%$328.09M$50M-5.0431Analyst ForecastDSGNDesign Therapeutics0.3488 of 5 stars$5.83+1.6%N/A+0.7%$326.88MN/A-5.2140Analyst Forecast Related Companies and Tools Related Companies AURA Alternatives REPL Alternatives LBRX Alternatives LRMR Alternatives ANNX Alternatives DMAC Alternatives EDIT Alternatives ALT Alternatives CTNM Alternatives DSGN Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:SCLX) was last updated on 10/24/2025 by MarketBeat.com Staff From Our PartnersWhat a Former CIA Agent Knows About the Coming Collapse This isn’t just another gold investing book—it’s a survival playbook written by a former CIA officer trained...Advantage Gold | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredTrump's Law S.1582: $21T Dollar Revolution ComingDo you have money in any of these banks? Chase. Bank of America. Citigroup. Wells Fargo. U.S. Bancorp. I...Brownstone Research | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?Trump Ally Says Congress Approved the Setup for a Digital Dollar 2.0 But according to Rep. Marjorie Taylor ...Goldco Precious Metals | SponsoredTrump’s new nightmare beginsPorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredMove $1,000 into this stock before Nov 6The End of Tesla? "Hold onto your Tesla stock." That's the message insiders at Tesla have been giving staff...Altimetry | SponsoredWhat Wall Street Won’t Say Out LoudDiscover the 7 key indicators before everyone else doesAmerican Alternative | SponsoredElon Warns “America Is Broke”. Trump’s Plan Inside.For the everyday American who's worked hard to build their nest egg, Trump preserved a IRS loophole that allow...American Hartford Gold | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Scilex Holding Company Please log in to your account or sign up in order to add this asset to your watchlist. Share Scilex With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
